Audentes Therapeutics Inc (BOLD) Expected to Announce Earnings of -$0.92 Per Share

Share on StockTwits

Analysts expect Audentes Therapeutics Inc (NASDAQ:BOLD) to report earnings per share (EPS) of ($0.92) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Audentes Therapeutics’ earnings. The lowest EPS estimate is ($1.02) and the highest is ($0.86). Audentes Therapeutics posted earnings of ($0.82) per share in the same quarter last year, which indicates a negative year over year growth rate of 12.2%. The firm is scheduled to announce its next quarterly earnings results on Thursday, March 14th.

According to Zacks, analysts expect that Audentes Therapeutics will report full year earnings of ($3.42) per share for the current fiscal year, with EPS estimates ranging from ($3.60) to ($3.06). For the next year, analysts expect that the business will post earnings of ($3.93) per share, with EPS estimates ranging from ($4.53) to ($3.28). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Audentes Therapeutics.

A number of equities research analysts recently weighed in on BOLD shares. Raymond James restated a “hold” rating on shares of Audentes Therapeutics in a research note on Wednesday, November 7th. JPMorgan Chase & Co. started coverage on Audentes Therapeutics in a research note on Monday, November 26th. They issued an “overweight” rating and a $35.00 price target on the stock. Mizuho restated a “buy” rating and issued a $45.00 price target on shares of Audentes Therapeutics in a research note on Wednesday, November 7th. HC Wainwright set a $33.00 price target on Audentes Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 7th. Finally, Zacks Investment Research upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research note on Tuesday, January 8th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $31.79.

BOLD traded up $0.23 during trading hours on Thursday, reaching $23.72. The company’s stock had a trading volume of 253,816 shares, compared to its average volume of 482,493. Audentes Therapeutics has a 52 week low of $17.95 and a 52 week high of $46.18. The stock has a market cap of $1.01 billion, a PE ratio of -6.98 and a beta of 1.79.

In other news, Director Louis G. Lange sold 24,000 shares of the stock in a transaction on Thursday, November 15th. The stock was sold at an average price of $22.49, for a total transaction of $539,760.00. Following the sale, the director now directly owns 345,799 shares of the company’s stock, valued at approximately $7,777,019.51. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Louis G. Lange sold 32,000 shares of the stock in a transaction on Monday, December 24th. The stock was sold at an average price of $18.62, for a total value of $595,840.00. Following the sale, the director now directly owns 325,799 shares in the company, valued at $6,066,377.38. The disclosure for this sale can be found here. Corporate insiders own 6.60% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BOLD. Partner Fund Management L.P. grew its holdings in shares of Audentes Therapeutics by 265.4% during the 3rd quarter. Partner Fund Management L.P. now owns 1,554,139 shares of the biotechnology company’s stock worth $61,528,000 after purchasing an additional 1,128,757 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Audentes Therapeutics by 15.8% during the 4th quarter. BlackRock Inc. now owns 2,974,591 shares of the biotechnology company’s stock worth $63,418,000 after purchasing an additional 406,605 shares in the last quarter. Artal Group S.A. grew its holdings in shares of Audentes Therapeutics by 140.0% during the 4th quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock worth $12,792,000 after purchasing an additional 350,000 shares in the last quarter. Nexthera Capital LP grew its holdings in shares of Audentes Therapeutics by 124.1% during the 3rd quarter. Nexthera Capital LP now owns 541,172 shares of the biotechnology company’s stock worth $21,425,000 after purchasing an additional 299,672 shares in the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of Audentes Therapeutics by 40.3% during the 3rd quarter. Alliancebernstein L.P. now owns 660,281 shares of the biotechnology company’s stock worth $26,141,000 after purchasing an additional 189,825 shares in the last quarter. 84.93% of the stock is currently owned by institutional investors.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Further Reading: What is a Stop Order?

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Reaves W H & Co. Inc. Has $31.48 Million Stake in Pinnacle West Capital Co.
Reaves W H & Co. Inc. Has $31.48 Million Stake in Pinnacle West Capital Co.
Williams Companies Inc  Position Increased by Reaves W H & Co. Inc.
Williams Companies Inc Position Increased by Reaves W H & Co. Inc.
Zacks: Brokerages Expect Woodward, Inc.Common Stock  Will Announce Quarterly Sales of $659.89 Million
Zacks: Brokerages Expect Woodward, Inc.Common Stock Will Announce Quarterly Sales of $659.89 Million
SPDR Blackstone / GSO Senior Loan ETF  Shares Sold by RiverFront Investment Group LLC
SPDR Blackstone / GSO Senior Loan ETF Shares Sold by RiverFront Investment Group LLC
Instructure Inc  Stake Increased by Mackenzie Financial Corp
Instructure Inc Stake Increased by Mackenzie Financial Corp
Mackenzie Financial Corp Purchases 3,740 Shares of Markel Co.
Mackenzie Financial Corp Purchases 3,740 Shares of Markel Co.


Leave a Reply

 
© 2006-2019 Zolmax.